Organization | Hospital Auxilio Mutuo

Hospital Auxilio Mutuo Report issue

Academic/Hospital Phase 2

Founded: San Juan Puerto Rico (1994)

Organization Overview

First Clinical Trial

2003

NCT01538641

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Auxilio Mutuo Cancer Center | Auxilio Mutuo Cancer Center/Hospital Auxilio Mutuo | Auxilio Mutuo Hospital Cancer Center | Fernando Cabanillas | Hospital Español Auxilio Mutuo | Hospital Español Auxilio Mutuo Inc.

Active Ingredients

Drugs in Phase 2 Trials (18)

bevacizumab (avastin) (1 trial)

capecitabine (xeloda) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (1 trial)

epirubicin (ellence) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (2 trials)

lenalidomide (revlimid) (1 trial)

leucovorin (1 trial)

methylprednisolone (medrol) (1 trial)

oxaliplatin (eloxatin) (3 trials)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (2 trials)

trastuzumab (herceptin) (1 trial)

valproic acid (depakene) (1 trial)

vincristine (oncovin) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (1)

graviola (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Aggression (Phase 2)

Breast Carcinoma In Situ (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma in Situ (Phase 2)

Carcinoma, Lobular (Phase 2)

Hodgkin Disease (Phase 2)

Inflammatory Breast Neoplasms (Phase 2)

Leukemia (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial APIs: 19